One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   NTRK Fusion Gene Positive Advanced Solid Tumor market

NTRK融合遺伝子陽性の進行性固形腫瘍市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測


[ 英語タイトル ] Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Size study, by Type (By Therapeutics, By Diagnostics), by End user (Hospitals and Clinics, Cancer Centers, Others), and Regional Forecasts 2020-2027


Product Code : BRCLHC00112111
Survey : Bizwit Research & Consulting LLP
Publish On : April, 2021
Number of Pages : 200
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
Enterprise User USD6250 / Question Form
Bayer AG
Teva Pharmaceuticals
Empire Genomics, LLC.
SeraCare Life Sciences
F. Hoffmann-La Roche Ltd
NeoGenomics Laboratories, Inc.
Glaxosmithkline plc
Merck & Co.
Daiichi Sankyo Company Limited
S Deciphera Pharmaceuticals, Inc.

[Report Description]

Global NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period 2020-2027. NTRK fusion gene positive cancers are those in which the NTRK gene has been mutated. While NTRK fusions are uncommon, accounting for less than 1% of solid tumors, the exact prevalence is unknown. NTRK fusion genes can be detected using DNA Next Generation Sequencing (NSG) technology. It has a high level of sensitivity and accuracy. It is capable of detecting gene partners with significant therapeutic effects. Foundation One does not detect NTRK fusions using commercially available techniques such as DNA NGS panels. Due to technological advances, the global NTRK fusion gene positive advanced solid tumors market is expected to expand rapidly over the forecast period. The demand for NTRK fusion gene positive advanced solid tumors would benefit from early screening and identification of NTRK mutation genes in people. Due to the advancement of new therapeutics in the near future for treating various forms of cancers, the global NTRK fusion gene positive advanced solid tumours market has a high potential. NTRK inhibitors, such as Entrectinib, marketed by Genentech Inc., were recently licensed by the FDA in 2019, for the treatment of NTRK fusion gene positive advanced solid tumors. Likewise,, SeraCare Life Sciences, a foremost in vitro diagnostics producer and clinical laboratory partner, launched an extended neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel in 2018, established in collaboration with Bayer. However, Poor healthcare infrastructure and high costs associated with genetic screening of NTRK fusion genes may hamper growth of NTRK fusion gene positive advanced solid tumors market growth over the forecast period of 2020-2027.

The regional analysis of the global NTRK Fusion Gene Positive Advanced Solid Tumors Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising cancer clinical research and development activities in the region. Whereas Europe is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027, due to early diagnosis and treatment adoption across the region.

Major market player included in this report are:
Bayer AG
Teva Pharmaceuticals
Empire Genomics, LLC.
SeraCare Life Sciences
F. Hoffmann-La Roche Ltd
NeoGenomics Laboratories, Inc.
Glaxosmithkline plc
Merck & Co.
Daiichi Sankyo Company Limited
S Deciphera Pharmaceuticals, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:


By Type:
By Therapeutics
By Diagnostics
By end user:
Hospitals and Clinics
Cancer Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027.

Target Audience of the Global NTRK Fusion Gene Positive Advanced Solid Tumors Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. NTRK Fusion Gene Positive Advanced Solid Tumour market , by Region, 2018-2027 (USD Billion)
1.2.2. NTRK Fusion Gene Positive Advanced Solid Tumour market , by Type, 2018-2027 (USD Billion)
1.2.3. NTRK Fusion Gene Positive Advanced Solid Tumour market , by end user, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Dynamics
3.1. NTRK Fusion Gene Positive Advanced Solid Tumour market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Growing Research and Development Activities
3.1.3. Increasing Prevalence of Cancer
3.1.4. Market Challenges
3.1.5. Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes
3.1.6. Market Opportunities
3.1.7. technical advancements in the tumour treatment
Chapter 4. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , by Type
5.1. Market Snapshot
5.2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by Type , Performance - Potential Analysis
5.3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Estimates & Forecasts by Type 2017-2027 (USD Billion)
5.4. NTRK Fusion Gene Positive Advanced Solid Tumour market , Sub Segment Analysis
5.4.1. By Therapeutics
5.4.2. By Diagnostics
Chapter 6. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , by End user
6.1. Market Snapshot
6.2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by End user, Performance - Potential Analysis
6.3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market Estimates & Forecasts by End user 2017-2027 (USD Billion)
6.4. NTRK Fusion Gene Positive Advanced Solid Tumour market , Sub Segment Analysis
6.4.1. Hospitals and Clinics
6.4.2. Cancer Centers
6.4.3. Others
Chapter 7. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , Regional Analysis
7.1. NTRK Fusion Gene Positive Advanced Solid Tumour market , Regional Market Snapshot
7.2. North America NTRK Fusion Gene Positive Advanced Solid Tumour market
7.2.1. U.S. NTRK Fusion Gene Positive Advanced Solid Tumour market
7.2.1.1. Type breakdown estimates & forecasts, 2017-2027
7.2.1.2. End user breakdown estimates & forecasts, 2017-2027
7.2.2. Canada NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3. Europe NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.3.1. U.K. NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.2. Germany NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.3. France NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.4. Spain NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.5. Italy NTRK Fusion Gene Positive Advanced Solid Tumour market
7.3.6. Rest of Europe NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.4.1. China NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.2. India NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.3. Japan NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.4. Australia NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.5. South Korea NTRK Fusion Gene Positive Advanced Solid Tumour market
7.4.6. Rest of Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumour market
7.5. Latin America NTRK Fusion Gene Positive Advanced Solid Tumour market Snapshot
7.5.1. Brazil NTRK Fusion Gene Positive Advanced Solid Tumour market
7.5.2. Mexico NTRK Fusion Gene Positive Advanced Solid Tumour market
7.6. Rest of The World NTRK Fusion Gene Positive Advanced Solid Tumour market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Bayer AG
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Teva Pharmaceuticals
8.2.3. Empire Genomics, LLC.
8.2.4. SeraCare Life Sciences
8.2.5. F. Hoffmann-La Roche Ltd
8.2.6. NeoGenomics Laboratories, Inc.
8.2.7. Glaxosmithkline plc
8.2.8. Merck & Co.
8.2.9. Daiichi Sankyo Company Limited
8.2.10. S Deciphera Pharmaceuticals, Inc.

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

List of Tables
TABLE 1. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , report scope
TABLE 2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by region 2017-2027 (USD Billion)
TABLE 3. Global NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by Type 2017-2027 (USD Billion)
TABLE 4. Global NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by End user 2017-2027 (USD Billion)
TABLE 5. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 6. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 7. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 8. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 9. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 10. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 11. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 12. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 13. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 14. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 15. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 16. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 17. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 18. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 19. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 20. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by region, estimates & forecasts, 2017-2027 (USD Billion)
TABLE 21. U.S. NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 22. U.S. NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 23. U.S. NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 24. Canada NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 25. Canada NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 26. Canada NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 27. UK NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 28. UK NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 29. UK NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 30. Germany NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 31. Germany NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 32. Germany NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 33. France NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 34. France NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 35. France NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 36. Spain NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 37. Spain NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 38. Spain NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 39. Italy NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 40. Italy NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 41. Italy NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 42. ROE NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 43. ROE NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 44. ROE NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 45. China NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 46. China NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 47. China NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 48. India NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 49. India NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 50. India NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 51. Japan NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 52. Japan NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 53. Japan NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 54. Australia NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 55. Australia NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 56. Australia NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 57. South Korea NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 58. South Korea NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 59. South Korea NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 60. ROPAC NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 61. ROPAC NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 62. ROPAC NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 63. Brazil NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 64. Brazil NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 65. Brazil NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 66. Mexico NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 67. Mexico NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 68. Mexico NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 69. ROLA NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 70. ROLA NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 71. ROLA NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 72. ROW NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts, 2017-2027 (USD Billion)
TABLE 73. ROW NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 74. ROW NTRK Fusion Gene Positive Advanced Solid Tumour market estimates & forecasts by segment 2017-2027 (USD Billion)
TABLE 75. List of secondary sources used in the study of global NTRK Fusion Gene Positive Advanced Solid Tumour market .
TABLE 76. List of primary sources used in the study of global NTRK Fusion Gene Positive Advanced Solid Tumour market .
TABLE 77. Years considered for the study.
TABLE 78. Exchange rates considered.

List of figures
FIG 1. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , research methodology
FIG 2. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , key trends 2019
FIG 5. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , growth prospects 2020-2027
FIG 6. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , porters 5 force model
FIG 7. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , pest analysis
FIG 8. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , value chain analysis
FIG 9. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 10. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 11. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 12. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 13. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 14. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 15. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 16. Global NTRK Fusion Gene Positive Advanced Solid Tumour market by segment, 2017 & 2027 (USD Billion)
FIG 17. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , regional snapshot 2017 & 2027
FIG 18. North America NTRK Fusion Gene Positive Advanced Solid Tumour market 2017 & 2027 (USD Billion)
FIG 19. Europe NTRK Fusion Gene Positive Advanced Solid Tumour market 2017 & 2027 (USD Billion)
FIG 20. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumour market 2017 & 2027 (USD Billion)
FIG 21. Latin America NTRK Fusion Gene Positive Advanced Solid Tumour market 2017 & 2027 (USD Billion)
FIG 22. Global NTRK Fusion Gene Positive Advanced Solid Tumour market , company market share analysis (2019)

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+